Gita Abhiraman
@gitaabhiraman.bsky.social
MD/PhD Student at Stanford interested in immune signaling, protein engineering, autoimmunity and cancer. PhD with Chris Garcia on a Hertz fellowship.
Many thanks to Chris Garcia, Karsten Householder, @graysonrodriguez.bsky.social, Caleb Glassman, Robert Saxton, our collaborators @retickerflynn.bsky.social, Cort Breuer, Venu Pillarisetty at UW, and several others in the Garcia lab who contributed to this work!
March 12, 2025 at 1:36 AM
Many thanks to Chris Garcia, Karsten Householder, @graysonrodriguez.bsky.social, Caleb Glassman, Robert Saxton, our collaborators @retickerflynn.bsky.social, Cort Breuer, Venu Pillarisetty at UW, and several others in the Garcia lab who contributed to this work!
Conversely, we show that cytokine adaptors can convert inflammatory cytokines into immunosuppressive signals. We show conversion of IL-23 or IL-17 into immunosuppressive IL-10 receptor agonists, with potential applications in autoimmune disease.
March 12, 2025 at 1:35 AM
Conversely, we show that cytokine adaptors can convert inflammatory cytokines into immunosuppressive signals. We show conversion of IL-23 or IL-17 into immunosuppressive IL-10 receptor agonists, with potential applications in autoimmune disease.
As proof of concept, we design cytokine adaptors that convert TGF-b or IL-10 into IL-2 receptor agonists to reverse T cell suppression, with potential applications in cancer therapy.
March 12, 2025 at 1:35 AM
As proof of concept, we design cytokine adaptors that convert TGF-b or IL-10 into IL-2 receptor agonists to reverse T cell suppression, with potential applications in cancer therapy.
Conversely, we show that cytokine adaptors can convert inflammatory cytokines into immunosuppressive signals. We show conversion of IL-23 or IL-17 into immunosuppressive IL-10 receptor agonists, with potential applications in autoimmune disease.
March 12, 2025 at 1:33 AM
Conversely, we show that cytokine adaptors can convert inflammatory cytokines into immunosuppressive signals. We show conversion of IL-23 or IL-17 into immunosuppressive IL-10 receptor agonists, with potential applications in autoimmune disease.
As proof of concept, we design cytokine adaptors that convert TGF-b or IL-10 into IL-2 receptor agonists to reverse T cell suppression, with potential applications in cancer therapy.
March 12, 2025 at 1:33 AM
As proof of concept, we design cytokine adaptors that convert TGF-b or IL-10 into IL-2 receptor agonists to reverse T cell suppression, with potential applications in cancer therapy.